PHIO - Phio Pharmaceuticals Corp. Short-Term Debt to Capital

Phio Pharmaceuticals is actively developing its INTASYL line to combat cancer by enhancing T-cells. The share price history on GURU.Markets, where the indicator stands at 0.00, is based on an RNA interference platform. Licensing deals with major players are strengthening the company's balance sheet. High barriers to entry are ensured by gene silencing patents and costly research, which limits competition in this sector.

This ratio determines the proportion of short-term liabilities within the equity structure, allowing investors to filter out market volatility and objectively assess liquidity risks. By analyzing the current short-term debt to equity value, one can confirm the financial stability of Phio Pharmaceuticals (PHIO), whose operational stability is supported by the seamless functioning of molecular laboratories and a strict maintenance protocol for research equipment.